View all AI CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.



Accreditation/ Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Resources

PER Pulse™ Recaps highlight key elements of the Advances in™ Immunotherapy: Emerging Agents and the Evolving Standard of Care in Advanced and Metastatic Bladder Cancers online CME activity.


Acknowledgment of Commercial Support

This activity is supported by an educational grant from Bristol-Myers Squibb.


Advances in™ Immunotherapy: Emerging Agents and the Evolving Standard of Care in Advanced and Metastatic Bladder Cancers


Release Date: November 4, 2016
Expiration Date: November 4, 2017
Media: Internet - based

Activity Overview 

The Advances in™ activity format, launched in 2007, has been designed to update and guide oncologists on new and emerging data regarding novel therapeutic agents with the potential to improve treatment, such as molecularly targeted agents, monoclonal antibodies, and immuno-oncology. Advances in™ Immunotherapy: Emerging Agents and the Evolving Standard of Care in Advanced and Metastatic Bladder Cancers will focus on treating bladder cancers with immunotherapy and will consist of video clips of interviews with thought leaders, Drs. Daniel Petrylak and David Quinn. These experts will discuss new data, provide perspective on how evolving concepts may impact future practice, explaining potential application to the clinic. 

CME/CE Activity Table of Contents

  • Pretest
  • Biology of Bladder Cancer and Key Biologic Pathways
  • Unmet Needs in the Treatment of Bladder Cancer
  • Rationale for Development of Immunotherapy for the Treatment of Advanced and Metastatic Bladder Cancer
  • Checkpoint Inhibitors for the Treatment of Advanced and Metastatic Bladder Cancer: Potential Clinical Implications of Emerging Data and Ongoing Clinical Trials
  • Evolving Role of Biomarker Analysis in the Treatment of Bladder Cancer and Its Potential Clinical Implications: Where Are We Now, and What Does the Future Hold?
  • Progress in Broad Molecular Testing and the Evolving Role of Liquid-Based Testing
  • Posttest
 

 

Instructions For This Activity & Receiving Credit

  • Once you begin the activity, please answer the demographic questions. This will allow you to proceed to the activity.
  • This activity contains one or more interactive questions. You may move forward through the activity; however, you may not go back to change answers or review content until you finish the activity.
  • At the end of the activity, an “Educational Content” link will be available for you to download content in PDF format for your reference.
  • If you close the Web browser after you complete the activity, the Educational Content link will disappear and you will need to review the activity in its entirety to once again access the link.
  • In order to receive a CME certificate, participants must complete the activity.
  • Click on the “Request Credits” link at the end of the activity. Complete the posttest and pass with a score of 70% or higher, complete the evaluation, and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.


Target Audience

This educational program is directed toward medical oncologists who treat patients with bladder cancers. Fellows, nurses, nurse practitioners, physician assistants and other healthcare professions (HCPs) involved in the treatment of bladder cancers are also invited to participate.


Educational Objectives

At the conclusion of this activity, you should be better prepared to: 
  • Describe the role of immunotherapy and emerging data from clinical trials in the treatment of patients with muscle-invasive bladder cancer (MIBC) and metastatic bladder cancer 
  • Describe the evolving role of biomarkers in the treatment of bladder cancer and its potential in treatment personalization 
  • Discuss advances in the development of emerging platforms and technologies for biomarker analysis in bladder cancer 


Faculty, Staff, and Planners' Disclosures

Faculty

Daniel P. Petrylak, MD
Professor of Medicine (Medical Oncology) and Urology
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Group
Yale Cancer Center
New Haven, CT
Disclosure: Grant/Research Support: Bayer, Bellicum, Dendreon, Sanofi Aventis, Johnson & Johnson, Exelixis, Ferring, Millennium, Medivation, Pfizer, Roche Laboratories, Tyme Technologies; Consultant: Bayer, Bellicum, Dendreon, Sanofi Aventis, Johnson & Johnson, Exelixis, Ferring, Millennium, Medivation, Pfizer, Roche Laboratories, Tyme Technologies. Stock/Shareholder: Bellicum, Tyme Technologies. 

David I. Quinn MBBS (Hons), PhD, FRACP, FACP 
Medical Director, Norris Cancer Hospital and Clinics
Head, Genitourinary Section 
Division of Medical Oncology
Associate Professor of Medicine
Kenneth J. Norris Jr. Comprehensive Cancer Center
Keck School of Medicine
University of Southern California
Los Angeles, CA
Disclosure: Grant/Research Support: Millennium, Genentech, Sanofi; Consultant: Astellas, Bayer, Pfizer, BMS, Merck, EMD Serono, Exelixis, Dendreon, Novartis, Peleton Therapeutics, AstraZeneca; Speaker’s Bureau: NIL; Stock/Shareholder: NIL; Other Support: NIL. 

The staff of Physicians’ Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests.


Disclosure Policy and Resolution of Conflicts of Interest (COI)

It is the policy of PER® to ensure the fair balance, independence, objectivity, and scientific objectivity in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
 
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this activity.

CME Provider Contact Information

Physicians’ Education Resource®, LLC
666 Plainsboro Road, Suite 356
Plainsboro, NJ 08536
Toll Free: 888-949-0045
Local: 609-378-3701
Fax: 609-257-0705
info@gotoper.com

Hardware And Software Requirements 

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)
  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
Minimum System Requirements (Mac OS)
  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise




Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
2627282930
Filter By